Published in Gene Therapy Weekly, March 4th, 2004
The financing also included an option to purchase an additional $15.9 million in warrants callable by Hyalozyme. Ritchie Capital, Cimarron Biomedical Investors, and Colt Ventures participated in the round. Brean Murray & Co., Inc., acted as placement agent. Kirkpatrick & Lockhart, LLP, acted as counsel to Grove Capital.
"Hyalozyme has successfully developed a recombinant human enzyme product that will dramatically improve current treatment options in the therapeutic areas of infertility, ophthalmology, and oncology," said Peter G. Geddes of Grove Capital. "The...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.